Shineco

SISI

Market cap $5.48M

Overview Fund Activity

6.09 USD

+0.03

0.5%

At close Updated Sep 12, 4:00 PM EDT

1 day

0.5%

5 days

20.59%

1 month

18.02%

3 months

-61.67%

6 months

-84.86%

Year to date

-94.14%

1 year

-98.73%

5 years

-99.98%

10 years

-100%

About: Shineco Inc aims to care for a healthy life and improve the quality of life by providing safe, efficient, and high-quality health products and services to society. The company has researched and developed various vitro diagnostic reagents and related medical devices to date, and it also produces and sells healthy and nutritious food.

Employees: 119

Consumer Staples Farm Products

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

0.01% more ownership

Funds ownership: 0.01% [Q1] → 0.03% (+0.01%) [Q2]

0% more funds holding

Funds holding: 5 [Q1] → 5 (+0) [Q2]

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

44% less capital invested

Capital invested by funds: $93.5K [Q1] → $52.4K (-$41.1K) [Q2]

See Fund Rankings

Financial journalist opinion

Based on 4 articles about SISI published over the past 30 days

Shineco (SISI) Ignites Growth: $8.7M Tech Deal & Major Singapore Alliance Unleash Dual Engines

BEIJING , Sept. 12, 2025 /PRNewswire/ -- Shineco Inc. (NASDAQ: SISI) ("Shineco" or the "Company"), a developer and commercializer of induced pluripotent stem cell (iPSC) technology platforms, today announced two major strategic advances.

Shineco (SISI) Ignites Growth: $8.7M Tech Deal & Major Singapore Alliance Unleash Dual Engines

Shineco Achieves Mass Production of High-Purity Physical Phospholipids, Breaking Foreign Monopoly and Unlocking Innovation Across Industries

BEIJING , Sept. 10, 2025 /PRNewswire/ -- Shineco Inc. (NASDAQ: SISI) ("Shineco" or the "Company"), a leading developer of induced pluripotent stem cell (iPSC) technology platforms, today announced that its subsidiary, Fuzhou Meidashan Biotechnology Co., Ltd.

Shineco Achieves Mass Production of High-Purity Physical Phospholipids, Breaking Foreign Monopoly and Unlocking Innovation Across Industries

Shineco (NASDAQ: SISI) & BICC: From "Tech On-Chain" to "Global Redeemability"--RWA Ecosystem Takes Off for Long-Term Growth

BEIJING , Aug. 27, 2025 /PRNewswire/ -- Shineco Inc. ("Shineco" or the "Company"; NASDAQ: SISI), a manufacturer of induced pluripotent stem cell (iPSC) technology platforms, has entered into a strategic cooperation agreement with Singapore-based BICC Pte Ltd to jointly promote the implementation and redemption of "on-chain cell assets" across multiple institutions and scenarios. This collaboration marks a new phase of "cross-enterprise redeemability" for cell assets on the blockchain, advancing the RWA ecosystem from "technical on-chain integration" to "real-world application.

Shineco (NASDAQ: SISI) & BICC: From "Tech On-Chain" to "Global Redeemability"--RWA Ecosystem Takes Off for Long-Term Growth

Shineco Unveils World's First On-Chain Cell Asset Tokenization Platform; Strategic Acquisition Expands Global Blockchain-Biotech Network

BEIJING , Aug. 20, 2025 /PRNewswire/ -- Shineco Inc. ("Shineco" or the "Company"; NASDAQ: SISI), a leading innovator in induced pluripotent stem cell (iPSC) technology, today announced the execution of a "Cellular Asset On-Chaining and Marketing Ecosystem Cooperation Agreement" with blockchain infrastructure provider Plus Me Limited. This partnership enables blockchain-based tokenization of biological cellular assets, facilitating seamless global transfers and auditable standardized custody, creating a novel 'Asset On-Chaining + Application Scenarios' model in cell therapy.

Shineco Unveils World's First On-Chain Cell Asset Tokenization Platform; Strategic Acquisition Expands Global Blockchain-Biotech Network

Shineco Establishes Biological Cell Digital Division to Integrate Biological Cell Assets and Blockchain Technology

BEIJING , Aug. 13, 2025 /PRNewswire/ -- Shineco Inc. ("Shineco" or the "Company"; NASDAQ: SISI), a manufacturer of induced pluripotent stem cell (iPSC) technology platforms, today announced the establishment of a Biological Cell Digital Business Division (the "Division"), and the appointment of Mr. Lin Hongguang as General Manager, to advance the integration of its biological cell assets and blockchain technology.

Shineco Establishes Biological Cell Digital Division to Integrate Biological Cell Assets and Blockchain Technology

Shineco, Inc. to Effect 50:1 Reverse Stock Split

Measure taken to Comply with Nasdaq Rule 5550(a)(2) Regarding Minimum Bid Price BEIJING, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Shineco, Inc. (Nasdaq:SISI) ("Shineco" or the "Company"), a provider of innovative diagnostic medical products and related medical devices, today announced that the Company's Board of Directors has approved a 50:1 reverse stock split of the Company's issued and outstanding common stock, par value $0.001 per share (the "Common Stock") to be effective 12:01 a.m., Eastern Time, on August 11, 2025.

Shineco, Inc. to Effect 50:1 Reverse Stock Split

Shineco Announces Acquisition of Medical Device Company

The Acquisition is Expected to Create Immediate Synergies with the Company's Existing Medical Device Business BEIJING, March 25, 2025 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a provider of innovative diagnostic medical products and related medical devices, announced today that on March 20, 2025, Shineco Life Science Group Hong Kong Co., Limited (“Shineco Life Science”), a subsidiary of the Company, entered into a Stock Purchase Agreement (“SPA”) with Yi Yang (the “Seller”), for 75% of an equity interest in FuWang (HK) International Company Limited (“FuWang Company”). The Seller is the current and only shareholder of FuWang Company, which specializes in the R&D, manufacturing, and commercialization of medical devices.

Shineco Announces Acquisition of Medical Device Company

Future FinTech Announces the Appointment of Hu Li as the New CEO

NEW YORK , Aug. 9, 2024 /PRNewswire/ -- Future Fintech Group Inc. (NASDAQ: FTFT), (hereinafter referred to as "Future FinTech", "FTFT" or the "Company"), a comprehensive financial and digital technology service provider, today announced that its Board of Directors (the "Board") approved the appointment of Mr. Hu Li as Chief Executive Officer ("CEO"), President and a member of the Board of the Company, effective August 5, 2024.

Future FinTech Announces the Appointment of Hu Li as the New CEO

Shineco Announces Closing of $2 Million Underwritten Public Offering

Beijing, July 15, 2024 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”) (NASDAQ: SISI), a provider of innovative diagnostic medical products and related medical devices, today announced the closing of its underwritten public offering of 1,869,160 shares of its common stock at a public offering price of $1.07 per share of common stock, for aggregate gross proceeds of approximately $2 million, prior to deducting underwriting discounts and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 280,374 shares of common stock at the public offering price per share, less the underwriting discounts to cover over-allotments, if any.

Shineco Announces Closing of $2 Million Underwritten Public Offering

Why Is Shineco (SISI) Stock Down 54% Today?

Shineco (NASDAQ: SISI ) stock is falling hard on Friday after the agricultural produce company announced the pricing of a public offering for its shares. This public offering has Shineco selling 1,869,160 shares of SISI stock for $1.07 each.

Why Is Shineco (SISI) Stock Down 54% Today?

See News Rankings

Charts implemented using Lightweight Charts™